News

Video

Deep and Sustained Responses in Patients With CLL Treated With Zanubrutinib or Zanubrutinib + Obinutuzumab in Phase 1/2 AU-003 and Phase 1b GA-101 Studies: A Report From the Zanubrutinib Extension Study

Author(s):

Constantine S. Tam, MD, MBBS

Dr. Constantine S. Tam presents an OncLive Rapid Readout on the zanubrutinib extension study, highlighting deep and durable responses with zanubrutinib, alone or in combination with obinutuzumab, in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients, with impressive 72-month progression-free survival rates and a favorable long-term safety profile.

Related Videos
Analyses of Minimal Residual Disease (MRD) Negativity Dynamics in the Phase 3 Imroz Study
Elacestrant real-world progression-free survival (rwPFS) of adult patients with ER+/HER2-, advanced breast cancer: a retrospective analysis using insurance claims in the United States
DB-12
5-Year Follow-Up of Cohort 1 from the SEQUOIA Study
RMC-9805
LGSOC 2024
Cemiplimab Monotherapy for First Line Advanced NSCLC Patients with PD-L1 Expression ≥50%: 5-y Outcomes of EMPOWER-Lung
Trastuzumab deruxtecan in patients with HER2+ advanced/metastatic breast cancer with or without brain metastases: DESTINY-Breast12 primary results
Phase 3 MIRASOL Trial: Updated Overall Survival Results of Mirvetuximab Soravtansine (MIRV) Versus Investigator’s Choice (IC) Chemotherapy in Patients (pts) With Platinum-Resistant Ovarian Cancer (PROC) and High Folate Receptor-Alpha (FR⍺) Expression
Related Content